Get the Stockscreener App
28.98
2.75%
0.7827
Alkermes Plc stock is traded at $28.98, with a volume of 746.61K.
It is up +2.75% in the last 24 hours and down -2.77% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$28.20
Open:
$28.38
24h Volume:
746.61K
Relative Volume:
0.31
Market Cap:
$4.79B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
14.86
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-0.98%
1M Performance:
-2.77%
6M Performance:
-1.28%
1Y Performance:
-1.31%
1-Day Range:
$28.19
$29.04
1-Week Range:
$27.89
$29.27
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.98 | 4.66B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
128.54 | 54.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.52 | 44.92B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.785 | 43.06B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.98 | 28.42B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
482.81 | 20.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
United StatesGoodwin Advises Avadel Pharmaceuticals On Increased Offer From Alkermes - Mondaq
How Analysts See the Alkermes Story Changing After Acquisition Moves and New Narcolepsy Data - Yahoo Finance
Is Alkermes plc (8AK) stock a fit for income portfoliosRecession Risk & Consistent Growth Stock Picks - newser.com
Alkermes stock rating reiterated at Neutral by H.C. Wainwright - Investing.com Australia
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Finviz
Will Alkermes plc (8AK) stock benefit from mergersWeekly Investment Recap & Community Supported Trade Ideas - newser.com
Is Alkermes plc (8AK) stock good for wealth creation2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Is Alkermes plc (8AK) stock among top earnings playsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
What momentum indicators show for Alkermes plc stockWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Will Alkermes plc (8AK) stock benefit from infrastructure billMarket Movers & Growth Focused Stock Pick Reports - newser.com
Applying Elliott Wave Theory to Alkermes plcWeekly Risk Report & Daily Chart Pattern Signals - newser.com
What recovery options are there for Alkermes plcMarket Trend Report & Reliable Entry Point Alerts - newser.com
Alkermes Fires Back In Bidding War With Lundbeck Over Avadel - Citeline News & Insights
Alkermes, Avadel Bump Deal To $2.37B After Alternate Bid - Law360
Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals
Alkermes increases offer for Avadel to $21 in cash plus CVR - Investing.com Nigeria
What data driven models say about Alkermes plc’s futureChart Signals & Proven Capital Preservation Tips - newser.com
Risk vs reward if holding onto Alkermes plcQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion - TradingView
Alkermes prevails over Lundbeck in Avadel bidding war - Pharmaceutical Technology
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri - Finviz
Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters
Avadel Pharmaceuticals Agrees to Alkermes’ Revised Acquisition Offer - PharmExec.com
Alkermes Faces Bidding Battle For Avadel Pharmaceuticals - Finimize
Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says - MarketScreener
Alkermes escalates bidding war; US biotech risks ‘falling behind’ China - BioPharma Dive
Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer - Contract Pharma
H Lundbeck A/S says noted that our offer for acquiring Avadel no longer is considered superior by their board, we are currently considering our options - MarketScreener
Alkermes (ALKS) Increases Buyout Offer for Avadel Pharmaceuticals (AVDL) - GuruFocus
Alkermes raises offer for Avadel acquisition and secures $1.5 billion loan facility - Investing.com Australia
How high can Alkermes plc stock goWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Why Alkermes plc stock is a must watch in 2025July 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Nov 03 '25 |
Sale |
30.38 |
9,000 |
273,442 |
69,740 |
1.84%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):